Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia

Abstract EN

Background.

Serum free light chains (sFLC), the most commonly detected paraprotein in CLL, were recently proposed as useful tools for the prognostication of CLL patients.

Objective.

To investigate the prognostic implication of sFLC and the summated FLC-kappa plus FLC-lambda in a CLL patients’ series.

Patients and Methods.

We studied 143 CLL patients of which 18 were symptomatic and needed treatment, while 37 became symptomatic during follow-up.

Seventy-two percent, 18%, and 10% were in Binet stage A, B and C, respectively.

Median patients’ followup was 32 months (range 4–228).

Results.

Increased involved (restricted) sFLC (iFLC) was found in 42% of patients, while the summated FLC-kappa plus FLC-lambda was above 60 mg/dL in 14%.

Increased sFLC values as well as those of summated FLC above 60 were related to shorter time to treatment (P=0.0005 and P=0.000003, resp.) and overall survival (P=0.05 and P=0.003, resp.).

They also correlated with β2-microglobulin (P=0.009 and P=0.03, resp.), serum albumin (P=0.009 for summated sFLC), hemoglobin (P<0.001), abnormal LDH (P=0.037 and P=0.001, resp.), Binet stage (P<0.05) and with the presence of beta symptoms (P=0.004 for summated sFLC).

Conclusion.

We confirmed the prognostic significance of sFLC in CLL regarding both time to treatment and survival and showed their relationship with other parameters.